We would like to thank our readers, subscribers and collaboration partners for a fruitful, eventful and fun Q1 + Q2 2017, and we wish you all a most wonderful summer!
Nordic Life Science will be back on August 2nd and provide you with the latest news from our exciting life science industry!
Until then, here are some vacation reading:
To round off this year’s Nordic Life Science Days, we asked Jonas Ekstrand, Director General at SwedenBIO, the founder of the event, a few questions. What’s your impressions of this year’s event? “Mainly positive. I have received both positive and constructive feedback from participants, they have for example enjoyed meeting companies…
If i was a scientist … … I would probably, or hopefully, be exploring the exciting world of the inner ear. Perhaps I would be able to transfect an auditory neuron, with a nano-particle and follow it in a super-resolved fluorescence microscope. I would also have had a great and…
PhaseBio Pharmaceuticals, Inc. a biopolymer-based drug manufacturer, has raised $40 million in a Series C round of funding, which includes a major share from AstraZeneca. Existing investors New Enterprise Associates, Hatteras Venture Partners and Johnson & Johnson Innovation were also involved in the financing round, according to BioSpace. “AstraZeneca is…
Immunovia announces a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than…
